Foreword
Dear reader,
BB Biotech maintains a concentrated, high-conviction portfolio of biotech companies. Our portfolio companies develop products that address unmet medical needs, showcasing high profit-growth potential and making a meaningful societal impact.
We adopt a business-driven approach to sustainability, backed by over 30 years of experience as an engaged and responsible investment company, with a focus on delivering long-term value for both our investors and society at large.
Over the past three decades, we have continually refined our responsible investing strategy, recognizing that there is much to learn in this dynamic field. Engaging with our portfolio companies on ESG matters is a journey that fosters ongoing learning for all involved.
In 2024, BB Biotech received an «A» rating for ESG from MSCI and improved its ESG rating to «B» from the Swiss rating agency Inrate. BB Biotech was again included in the SPI ESG Index.
In 2024 BB Biotech was again included in the SPI ESG Index.
By incorporating ESG considerations into our investment strategies, processes, and ownership practices, we believe we can enhance long-term returns for our shareholders and benefit society as a whole.
As a leading biotech investor, we are uniquely positioned to contribute to positive societal improvement with new medicines being developed by our portfolio companies. We prioritize investments in companies and assets that addresses unmet medical needs. The core mission of biotechnology is to meet human needs and improve quality of life, positioning the sector among the fastest-growing industries.
BB Biotech´s portfolio companies saw a number of new approvals in 2024:
Company | Product | Treatment of | |||
Vertex/Crispr | Casgevy | Transfusion dependant beta thalassemia | |||
Esperion | Nexletol | Label expansion – reduce risk of cardiovascular events | |||
Moderna | mResvia | RSV infection, older adults | |||
Argenx | Vyvgart Hytrulo | Chronic inflammatory demy polyneuropathy | |||
Incyte | Axatilimab | 3L-chronic graft-versus-host disease | |||
Neurocrine | Crenessity | Congenital adrenal hyperplasia | |||
Ionis | Tryngolza | Familial chylomicronemia syndrome | |||
Vertex | Alyftrek | Cystic fibrosis | |||
Looking ahead, we anticipate our portfolio companies will contribute to several new drug approvals, as many of them currently have numerous product candidates in clinical development.
BB Biotech AG is committed to sustainability and it is an important priority for our Board of Directors.
We remain dedicated to providing transparency regarding our processes and results, ensuring that our investors have the information they need to succeed.
